T cells (no tumors) (cpm) T+ HEp2-vec (cpm) T+HEp2-IB(S32AS36A) (cpm)
  T cells -/+IL2   - IFN-g    + IFN-g - IFN-g   + IFN-g
Exp#1 - 4259 ± 402 4514 ± 1066 3889 ± 1268 8729 ± 558 5562 ± 398
  + 17866 ± 205 8937 ± 394 6866 ± 564 47189 ± 1327 ND
Exp #2            
  - 1976 ± 100 3516 ± 535 3588 ± 1088 3676 ± 524 3038 ± 365
  + 14273 ±1435 8364 ±1049 6216 ± 495 25940 ±1504 19605 ± 1295
Exp #3            
  - 1760 ± 390 4635 ± 2726 4995 ± 1381 5267 ± 1385 6153 ± 2767
  + 18184 ± 1128 10311 ± 1603 6784 ± 1769 32174 ± 2513 27374 ± 3589
Purified CD8+ T cells (1X106 cells per sample) were treated with IL-2 (500u/ml) before their co-culture with untreated and IFN-γ pre-treated (200u/ml), irradiated vectoralone and IκB(S32AS36A) transfected HEp2 cells (E:T ratio of 1:1). After 18 days of incubation 100 μl of each sample were removed and added in triplicates to 96 well flat bottom plates and the incubation continued in the presence of 1μCi/well of 3H thymidine for another 16-18 hours. IFN-γ pre-treated HEp2 cell transfectants were washed three times before they were added to CD8+ T cells. The p value for the differences between the co-cultures of IL-2 treated CD8+ T cells with control HEp2 cells vs. IκB(S32AS36A) transfected HEp2 cells were less than 0.05. ND (not done)
Table 3: Inhibition of CD8+ T cell thymidine incorporation after interaction of CD8+ T cells with vector-alone transfected HEp2 cells but not with HEp2-IκB(S32AS36A) cells.